Compare Stocks: MGNX, ALMS, CVAC, and KURA

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALMS Alumis	$7.29 -2.0%	$19.95	$3.76 ▼ $31.35	$1.05B	-0.81	4.84 million shs	2.60 million shs
CVAC CureVac	$4.66	$4.66	$3.13 ▼ $5.72	$1.05B	1.77	992,546 shs	N/A
KURA Kura Oncology	$10.86 -1.6%	$11.22	$7.36 ▼ $13.90	$1.04B	0.44	1.79 million shs	1.77 million shs
MGNX MacroGenics	$3.80	$4.07	$1.29 ▼ $5.08	$262.45M	1.22	425,893 shs	571,325 shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALMS Alumis	-8.26%	-6.30%	-67.69%	-70.28%	+81.46%
CVAC CureVac	0.00%	0.00%	0.00%	0.00%	-13.06%
KURA Kura Oncology	-5.88%	-1.43%	-10.97%	+6.56%	+33.98%
MGNX MacroGenics	-7.77%	-6.86%	-5.47%	-18.45%	+128.92%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALMS Alumis	$7.29 -2.0%	$19.95	$3.76 ▼ $31.35	$1.05B	-0.81	4.84 million shs	2.60 million shs
CVAC CureVac	$4.66	$4.66	$3.13 ▼ $5.72	$1.05B	1.77	992,546 shs	N/A
KURA Kura Oncology	$10.86 -1.6%	$11.22	$7.36 ▼ $13.90	$1.04B	0.44	1.79 million shs	1.77 million shs
MGNX MacroGenics	$3.80	$4.07	$1.29 ▼ $5.08	$262.45M	1.22	425,893 shs	571,325 shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALMS Alumis	-8.26%	-6.30%	-67.69%	-70.28%	+81.46%
CVAC CureVac	0.00%	0.00%	0.00%	0.00%	-13.06%
KURA Kura Oncology	-5.88%	-1.43%	-10.97%	+6.56%	+33.98%
MGNX MacroGenics	-7.77%	-6.86%	-5.47%	-18.45%	+128.92%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALMS Alumis	2.85	Moderate Buy	$33.27	356.42% Upside
CVAC CureVac	1.00	Sell	N/A	N/A
KURA Kura Oncology	2.75	Moderate Buy	$25.40	133.89% Upside
MGNX MacroGenics	2.17	Hold	$6.33	66.67% Upside

Current Analyst Ratings Breakdown

Latest MGNX, ALMS, CVAC, and KURA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/16/2026	ALMS Alumis	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
9/3/2026	ALMS Alumis	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Neutral
9/2/2026	ALMS Alumis	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$55.00 ➝ $37.00
9/2/2026	ALMS Alumis	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$39.00 ➝ $29.00
9/2/2026	ALMS Alumis	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$51.00 ➝ $25.00
9/2/2026	ALMS Alumis	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$25.00 ➝ $15.00
9/1/2026	ALMS Alumis	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$27.00
9/1/2026	ALMS Alumis	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$51.00 ➝ $25.00
9/1/2026	ALMS Alumis	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
8/24/2026	KURA Kura Oncology	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$24.00
8/24/2026	KURA Kura Oncology	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$24.00

(Data available from 9/24/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALMS Alumis	$24.05M	39.23	N/A	N/A	$2.88 per share	2.53
CVAC CureVac	$70.74M	14.78	$0.99 per share	4.73	$3.36 per share	1.39
KURA Kura Oncology	$67.48M	14.32	N/A	N/A	$2.00 per share	5.43
MGNX MacroGenics	$149.50M	1.62	N/A	N/A	$0.88 per share	4.32

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALMS Alumis	-$243.32M	-$3.86	N/A	N/A	N/A	-5,933.46%	-93.15%	-74.50%	11/12/2026 (Estimated)
CVAC CureVac	$175.50M	$0.72	6.47	N/A	N/A	199.92%	-23.03%	-19.09%	N/A
KURA Kura Oncology	-$278.67M	-$3.37	N/A	N/A	N/A	-384.30%	-207.18%	-45.17%	11/3/2026 (Estimated)
MGNX MacroGenics	-$74.62M	-$0.22	N/A	N/A	N/A	-8.70%	-109.26%	-18.70%	11/11/2026 (Estimated)

Latest MGNX, ALMS, CVAC, and KURA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	ALMS Alumis	-$0.7670	-$1.11	-$0.3430	-$1.11	$3.65 million	$1.66 million
8/13/2026	Q2 2026	MGNX MacroGenics	-$0.0779	$0.31	+$0.3879	$0.31	$59.14 million	$32.83 million
8/12/2026	Q2 2026	KURA Kura Oncology	-$0.8773	-$0.77	+$0.1073	-$0.77	$20.16 million	$20.87 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALMS Alumis	N/A	N/A	N/A	N/A	N/A
CVAC CureVac	N/A	N/A	N/A	N/A	N/A
KURA Kura Oncology	N/A	N/A	N/A	N/A	N/A
MGNX MacroGenics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALMS Alumis	N/A	6.74	6.74
CVAC CureVac	0.03	3.70	3.69
KURA Kura Oncology	0.12	4.73	4.71
MGNX MacroGenics	N/A	2.96	2.96

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALMS Alumis	N/A
CVAC CureVac	17.26%
KURA Kura Oncology	N/A
MGNX MacroGenics	96.89%

Insider Ownership

Company	Insider Ownership
ALMS Alumis	33.70%
CVAC CureVac	2.15%
KURA Kura Oncology	7.60%
MGNX MacroGenics	13.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALMS Alumis	239	129.43 million	85.82 million	N/A
CVAC CureVac	880	224.34 million	219.52 million	No Data
KURA Kura Oncology	260	88.96 million	82.20 million	Optionable
MGNX MacroGenics	293	63.70 million	55.04 million	Optionable

MGNX, ALMS, CVAC, and KURA Headlines

Recent News About These Companies

Avidity Biosciences (NASDAQ:RNA) vs. MacroGenics (NASDAQ:MGNX) Head to Head Comparison

September 24 at 6:28 AM | americanbankingnews.com

MacroGenics stock holds at USD 4.12 as cash strength stands out

September 23 at 6:09 PM | ad-hoc-news.deA

MacroGenics, Inc. (NASDAQ:MGNX) Given Average Rating of "Hold" by Brokerages

September 22 at 4:15 AM | americanbankingnews.com

MacroGenics, Inc. (NASDAQ:MGNX) Receives Consensus Recommendation of "Hold" from Analysts

September 22 at 4:13 AM | marketbeat.com

MacroGenics stock edges lower as biotech analysts highlight risk and upside

September 19, 2026 | ad-hoc-news.deA

MacroGenics consensus price target rises 12% to $9.52

September 14, 2026 | msn.com

MacroGenics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

September 9, 2026 | globenewswire.com

MacroGenics: Inexpensive ADC/TCE Biotech With Multiple Catalysts Ahead

September 9, 2026 | seekingalpha.com

BlackRock Inc. Takes $21.62 Million Position in MacroGenics, Inc. $MGNX

September 3, 2026 | marketbeat.com

MacroGenics, Inc. (NASDAQ:MGNX) Given Average Rating of "Hold" by Analysts

August 28, 2026 | marketbeat.com

Connor Clark & Lunn Investment Management Ltd. Purchases New Position in MacroGenics, Inc. $MGNX

August 28, 2026 | marketbeat.com

Bank of America Corp DE Buys 564,094 Shares of MacroGenics, Inc. $MGNX

August 26, 2026 | marketbeat.com

MacroGenics (NASDAQ:MGNX) VP Sells $129,085.75 in Stock

August 21, 2026 | insidertrades.com

Is MacroGenics (MGNX) Stock Outpacing Its Medical Peers This Year?

August 20, 2026 | zacks.com

MacroGenics (MGNX) Reports Q2 Loss, Lags Revenue Estimates

August 13, 2026 | zacks.com

MacroGenics Reports Second Quarter 2026 Financial Results, Streamlined Operating Model and Strengthened Financial Position

August 13, 2026 | globenewswire.com

MacroGenics, Inc.: MacroGenics Announces Achievement of $10 Million Milestone Following Gilead's Exercise of Option to License Preclinical Bispecific Program

August 12, 2026 | finanznachrichten.de

MacroGenics Announces Achievement of $10 Million Milestone Following Gilead's Exercise of Option to License Preclinical Bispecific Program

August 11, 2026 | globenewswire.com

MacroGenics: Whipsaws On Clinical Data, But The Big Picture Is Still Important

July 27, 2026 | seekingalpha.com

MacroGenics Advances MGC026 in Phase 1 Oncology Trial

July 25, 2026 | theglobeandmail.com

MacroGenics slips after early-stage trial data for lead asset

July 24, 2026 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

MGNX, ALMS, CVAC, and KURA Company Descriptions

Alumis NASDAQ:ALMS

$7.29 -0.15 (-2.02%)

Closing price 04:00 PM Eastern

Extended Trading

$7.38 +0.09 (+1.21%)

As of 07:57 PM Eastern

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words "allumer"-French for illuminate-and "immunis"-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule. ESK-001 has demonstrated significant therapeutic effect in our Phase 2 program in patients with PsO, which we define as moderate-to-severe plaque psoriasis (PsO), and is currently being evaluated in an additional Phase 2 clinical trial in patients with systemic lupus erythematosus (SLE), for which we expect to report results in 2026. With the favorable results in our Phase 2 clinical trial in PsO, we intend to initiate multiple Phase 3 clinical trials of ESK-001 in the second half of 2024 in this indication. TYK2 genetic mutations are associated with a strong protective effect in multiple sclerosis, motivating us to develop our second product candidate, A-005, as a CNS-penetrant, allosteric TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases. In April 2024, we initiated our Phase 1 program of A-005 in healthy volunteers and expect to report initial results by the end of 2024. We utilize our proprietary precision data analytics platform, biological insights and team of experienced research and development experts to deepen our understanding of disease pathologies, accelerate research and development and increase the probability of clinical success. Our collective insights informed our selection of TYK2 as the target for our two lead programs. Beyond TYK2, our proprietary precision data analytics platform and drug discovery expertise have led to the identification of additional preclinical programs that exemplify our precision approach. We recognize that patients living with immune-mediated diseases need alternatives to currently available therapies. Despite recent advances and innovations in the treatment of immune-mediated diseases, many patients continue to suffer, cycling through currently approved therapies while looking for a solution that alleviates the debilitating impact of their disease without life-limiting side effects. Addressing the needs of these patients is why we exist. We are pioneering a precision approach that leverages insights derived from powerful data analytics to select the right target, right molecule, right indication, right patient, right endpoint and right combination to dramatically improve patient outcomes. We believe that combining our insights with an integrated approach to drug development will produce the next generation of treatments to address immune dysfunction. We were founded in January 2021 as a Delaware corporation under the name FL2021-001, Inc. We changed our name to Esker Therapeutics, Inc. in March 2021, and subsequently to Alumis Inc. in January 2022. Our principal executive offices are located at 280 East Grand Avenue, South San Francisco, California.

CureVac NASDAQ:CVAC

$4.66 0.00 (0.00%)

As of 09/23/2026

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza. The company develops CV8102, which is in Phase 1 clinical trial for treating melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CVGBM for treating cancer. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.

Kura Oncology NASDAQ:KURA

$10.86 -0.18 (-1.63%)

Closing price 04:00 PM Eastern

Extended Trading

$10.90 +0.04 (+0.41%)

As of 07:49 PM Eastern

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification. The company was founded in 2014 and is headquartered in San Diego, California.

MacroGenics NASDAQ:MGNX

$3.80 0.00 (0.00%)

Closing price 04:00 PM Eastern

Extended Trading

$3.80 0.00 (-0.13%)

As of 07:30 PM Eastern

MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, a humanized monoclonal antibody targeting programmed death receptor-1; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest MGNX, ALMS, CVAC, and KURA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest MGNX, ALMS, CVAC, and KURA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

MGNX, ALMS, CVAC, and KURA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

MGNX, ALMS, CVAC, and KURA Company Descriptions

Alumis NASDAQ:ALMS

CureVac NASDAQ:CVAC

Kura Oncology NASDAQ:KURA

MacroGenics NASDAQ:MGNX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest MGNX, ALMS, CVAC, and KURA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest MGNX, ALMS, CVAC, and KURA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

MGNX, ALMS, CVAC, and KURA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

MGNX, ALMS, CVAC, and KURA Company Descriptions

Alumis NASDAQ:ALMS

CureVac NASDAQ:CVAC

Kura Oncology NASDAQ:KURA

MacroGenics NASDAQ:MGNX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools